Typ-2-Diabetes: Breitere Zulassung für Empagliflozin/Linagliptin
Frontiers | Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
Herzinsuffizienz bei Diabetes mellitus | roche.de
JCM | Free Full-Text | Ultrasonography Measurement of Renal Dimension and Its Correlation with Age, Body Indices, and eGFR in Type 1 Diabetes Mellitus Patients: Real World Data in Taiwan
Pharmaceuticals | Free Full-Text | Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1–4
Neue Leitlinie für das Diabetesmanagement bei chronischer Nierenerkrankung | SpringerLink
Frontiers | Implications of a Family History of Diabetes and Rapid eGFR Decline in Patients With Type 2 Diabetes and Biopsy-Proven Diabetic Kidney Disease
Pharmacological Management of Glycaemia in People with Type 2 Diabetes and Renal Impairment - GPnotebook Education
Neue Diabetemedikamente Typ-2-Diabetes - diabetes-news : diabetes-news
Egfr Type 2 Diabetes - NSO - National Solar Observatory
Diabetes und Nierenerkrankung: Prävention und Therapie | Diabetes Forum
Antihyperglycemic medications and renal function - Diabetes Canada
From Dipsticks to GFR - How to Evaluate Kidney Function - Diabetes Education Services
GPnotebook shortcut - medication in diabetes and kidney disease - General Practice notebook
Decline of estimated glomerular filtration rate (eGFR) in all patients... | Download Scientific Diagram
Epidermal growth factor receptor signaling and the progression of diabetic nephropathy - Koya - 2015 - Journal of Diabetes Investigation - Wiley Online Library
Testing for kidney disease in type 2 diabetes: consensus statement and recommendations - DiabetesontheNet
Diabetes mellitus Typ 2 - 11 - 2019 - Heftarchiv - AMT
Diabetes mellitus induces EC Egfr signaling. A, Representative flow... | Download Scientific Diagram
Typ-2-Diabetestherapie mit Empagliflozin: Breiteres eGFR-Spektrum
Testing for kidney disease in type 2 diabetes: consensus statement and recommendations - DiabetesontheNet
Frontiers | A Validation Study on eGFR Equations in Chinese Patients With Diabetic or Non-diabetic CKD
Chronic administration of nano-sized PAMAM dendrimers in vivo inhibits EGFR-ERK1/2-ROCK signaling pathway and attenuates diabetes-induced vascular remodeling and dysfunction - ScienceDirect
